Partnering to Innovate in Rare Disease
Innovation has been in our DNA for more than a century. Our teams are relentlessly driving advances across immunoglobulins, immunology, haematology, cardiovascular, and renal disease. In each of these areas, our commitment to patients is unwavering, fuelled by a belief that the next breakthrough might come from anywhere, or anyone. That’s why we place such a high value on external innovation - working closely with organizations outside our walls that have unique technologies, assets and equipment to help address patients’ unmet needs around the globe.
Our Approach
At CSL, we bring more than just funding to the table. Underpinned by a true collaborative spirit, we offer global infrastructure, deep expertise in product and clinical development and commercialization, and a proven ability to scale and deliver therapies worldwide.
For our partners, this means access to resources that can turn ideas into real-world impact. Whether you’re a start-up with a promising asset or a mature company seeking to expand your reach, CSL is uniquely positioned to help you fast-track your progress. Our doors are open to new ideas, new partnerships, and new ways of working that can deliver the next generation of therapies faster, further, and for more people in need.
We leverage innovative approaches to meet the diverse needs of biotechs

Our Areas of Interest
- Primary and Secondary Immunodeficiency Disorders
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Alpha 1 Antitrypsin Deficiency
Immunoglobulins
- Primary and Secondary Immunodeficiency Disorders
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Alpha 1 Antitrypsin Deficiency
Hematology
- Acute hemorrhage control
- Hemophilia A/B
- Von Willebrand's Disease
- Congenital bleeding disorders
- Iron metabolism
- Sickle Cell Disease
- Acute thrombotic conditions
Immunology
- CIDP and related Neuroimmunology Diseases
- Inclusion Body Myositis
- Myasthenia Gravis
- Dermatomyositis and other Idiopathic Inflammatory Myopathies (IIMs)
- Sjogren's Disease
- Chronic GvHD
- Chronic active antibody-mediated rejection
Renal & Cardiovascular
- Rare renal diseases; e.g. IgA Nephropathy, ANCA-associated vasculitis, Alport Syndrome, ADPKD, FSGS CKD/Dialysis Setting
- High cardiovascular risk e.g., MACE in ESKD, Pulmonary Embolism, Acute Ischemic Stroke
- Rare cardiovascular diseases with a speciality focus
- Iron Replacement
Some of Our Partnerships
CSL and VarmX: Partnering to Develop First-in-Class Investigational Coagulation Treatment
CSL and Lilly enter Licensing Agreement for clazakizumab
CSL and Travere Therapeutics: Delivering an Innovative IgA Nephropathy Therapy Together